Abbott's Humira keeps Crohn's patients in remission, data shows

By Elaine Rigoli

Tampa, Fla., May 22 - Abbott Laboratories announced results from a study showing patients with moderate to severely active Crohn's disease treated with Humira (adalimumab) were more likely to maintain clinical remission through one year than patients receiving a placebo, regardless of the frequency of the dosing regimen.

The company said the data will support Abbott's anticipated regulatory filing for an indication for Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract.

Crohn's disease is the fourth of six autoimmune diseases targeted for Humira therapy, the company said in a news release.

Data showed that remission rates were maintained through 56 weeks in patients who demonstrated response to Humira during a four-week open-label induction phase, the release said.

Co-primary endpoints in Charm were clinical remission rates at week 26 and week 56. The data showed significantly higher remission rates at weeks 26 and 56 versus a placebo, among patients with a decrease greater than or equal to 70 points at week four.

In addition, the percentage of patients in clinical remission on the two dosing regimens was comparable, the release said.

Located in Abbott Park, Ill., Abbott is a global health care company devoted to the development, manufacture and marketing of pharmaceuticals and medical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.